Jove
Visualize
お問い合わせ
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. 2014年欧州心臓病学会 (evidence-hcm) の急性心臓死予防に関する国際外部検証研究
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. 2014年欧州心臓病学会 (evidence-hcm) の急性心臓死予防に関する国際外部検証研究

関連する実験動画

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

2014年欧州心臓病学会 (EVIDENCE-HCM) の急性心臓死予防に関する国際外部検証研究

Constantinos O'Mahony1,2,3, Fatima Jichi4, Steve R Ommen5

  • 1St. Bartholomew's Centre for Inherited Cardiovascular Disease, St Bartholomew's Hospital, West Smithfield, London, United Kingdom (C.O., S.A.M., O.P.G., J.M., N.S., P.M.E.). drcostasomahony@gmail.com.

Circulation
|December 2, 2017

PubMed で要約を見る

まとめ
この要約は機械生成です。

HCM Risk-SCDモデルは,心筋縮性心筋症患者の突然死 (SCD) のリスクを正確に特定し,予防的な implantable cardioverter defibrillatorの決定に役立ちます.

科学分野:

  • 心臓病科
  • 臨床リスクの階層化
  • 電気生理学

背景:

  • 急性心臓死 (SCD) のリスクのある高縮性心筋病 (HCM) 患者の特定は,予防的なインプラント可能な心筋動器 (ICD) のインプラントに不可欠です.
  • 欧州心臓学会 (ESC) の2014年のガイドラインでは,5年間のSCDリスクを推定するためにHCMリスク-SCDモデルを導入しました.

研究 の 目的:

  • 2014年のESC HCMリスク-SCDモデルの予測精度を外部で検証する.
  • 多様で国際的な患者集団でのモデルのパフォーマンスを評価する.

主な方法:

  • 観察的,遡及的,縦断的なコホート研究.
  • 複数の地域における3703人の患者のデータを用いてHCMリスク- SCDモデルの検証.
  • カリブレーション,差別 (C指数),D統計の分析

主要な成果:

  • HCMリスク-SCDモデルは,1.02の校正傾斜と0.70のC指数で良好なパフォーマンスを示しました.
  • 完全な症例分析では,予測される5年SCDリスク≥6%の患者は,8. 9%の発生率を観察した.
  • このモデルは,高リスク患者 (予測リスク≥6%) の13件のICD移植ごとに,SCDから1人の命を救うことができると示唆しています.
キーワード:
心筋病 縮症突然の心臓発作による死亡インプラント式除細動器予測するリスク評価

さらに関連する動画

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

823

関連する実験動画

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

18.0K
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

823

関連する概念動画

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

539
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
539
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

489
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
489
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

605
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
605
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

632
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
632
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

638
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
638
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

611
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
611
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

結論:

  • HCMリスク- SCDモデルは,高縮性心筋病患者の正確な予後情報を提供します.
  • このモデルは,突然の心臓死のリスクが最も高い個人を対象に,インプラント可能なカーディオバーター・デフィブリレーター療法を効果的に導くことができます.